Staner L, Luthringer R, Macher J-P
Unité d'Exploration des Rythmes Veille-Sommeil et FORENAP, Centre Hospitalier de Rouffach, 27, rue du 4e RSM, 68250 Rouffach.
Rev Neurol (Paris). 2003 Nov;159(11 Suppl):6S48-55.
Most pharmacotherapeutic treatments designed to treat insomnia target GABAergic activity globally in the brain. Development of new molecules having a more specific activity pathway should improve treatment efficacy and acceptance. Both subjective and objective criteria are needed to study drug efficacy. Data regarding drug effects on polysomnographic recordings are mandatory for the development of hypnotics. Whether the drug-induced sleep is comparable to normal sleep is tackled with the spectral analysis of the sleep EEG. Residual drug effects are assessed with a package of psychomotor and neurocognitive tests, and with the driving simulator test Clinical studies investigating drug efficacy and tolerability have to be conducted on large groups of patients carefully selected using polysomnographic recordings. Our knowledge about sleep will undoubtedly soon become available for treatment of insomnia.
大多数旨在治疗失眠的药物治疗方法都是针对大脑中的γ-氨基丁酸能活性进行整体调节。开发具有更特定活性途径的新分子应能提高治疗效果和可接受性。研究药物疗效需要主观和客观标准。关于药物对多导睡眠图记录影响的数据对于催眠药物的开发至关重要。通过睡眠脑电图的频谱分析来探讨药物诱导的睡眠是否与正常睡眠相当。通过一系列心理运动和神经认知测试以及驾驶模拟器测试来评估残留药物效应。必须对使用多导睡眠图记录精心挑选的大量患者群体进行研究药物疗效和耐受性的临床研究。我们对睡眠的认识无疑很快将可用于失眠的治疗。
